Dollars for vectors
Why crossovers flooded series D for gene therapy play RegenxBio
RegenxBio Inc. has tapped investors for more than $100 million this year, including last week's $70.5 million series D round, but may return for more if its predictions of consolidation in the gene therapy space materialize. Finding additional dollars shouldn't be too hard, as RegenxBio had originally planned to raise $50-$60 million and found the round was about 3x oversubscribed with heavy participation from crossover investors.
New investor Vivo Capital led the series D along with existing investors Venrock and Brookside Capital. Other investors included Janus Capital, Jennison Associates, Perceptive Advisors, QVT Financial, Tourbillon Global Ventures, Sectoral Asset Management, Cormorant Asset Management, Foresite Capital, RTW Investments, two undisclosed investment funds and existing investors Deerfield Management and Fidelity Biosciences...